12:00 AM
 | 
Feb 25, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Bavituximab: Updated Phase IIb data

Updated data based on the completion of an earlier review of discrepancies from a double-blind, international Phase IIb trial in 121 patients with second-line locally advanced or metastatic non-squamous NSCLC showed that 3 mg/kg bavituximab plus docetaxel led to a median OS, a secondary endpoint, of 11.7 months vs. 7.3 months for the control arm (p=0.217). In the updated analysis, the control arm consisted of the combined placebo and 1...

Read the full 326 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >